title: Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome.
abstract: BACKGROUND
  Recurrence in the pelvis after resection of a rectal or rectosigmoid cancer presents a dilemma. Resection offers the only reasonable probability for cure, but at the cost of marked perioperative morbidity and potential mortality. Clinical decision making remains difficult.
  
  
  METHODS
  Patients who underwent resection with curative intent for isolated pelvic recurrences after curative colorectal surgery from 1988 through 2003 were reviewed retrospectively. Clinical and pathological factors, salvage operations, and complications were recorded. The primary measured outcome was overall survival. Univariate and multivariate analyses were conducted to identify prognostic factors of improved outcome.
  
  
  RESULTS
  Ninety patients underwent an attempt at curative resection of a pelvic recurrence; median follow-up was 31 months. Complications occurred in 53% of patients. Operative mortality occurred in 4 (4.4%) of 90 patients. Median overall survival was 38 months, and estimated 5-year survival was 40%. A total of 51 of 86 patients had known recurrences (15 local, 16 distant, 20 both). Multivariate analysis revealed that preoperative carcinoembryonic antigen level and final margin status were statistically significant predictors of outcome.
  
  
  CONCLUSIONS
  The resection of pelvic recurrences after colorectal surgery for cancer can be performed with low mortality and good long-term outcome; however, morbidity from such procedures is high. Low preoperative carcinoembryonic antigen and negative margin of resection predict improved survival.
authors.affiliation: Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
authors.forename: Leonard R
authors.initials: LR
authors.lastname: Henry
authors.forename: Elin
authors.initials: E
authors.lastname: Sigurdson
authors.forename: Eric A
authors.initials: EA
authors.lastname: Ross
authors.forename: John S
authors.initials: JS
authors.lastname: Lee
authors.forename: James C
authors.initials: JC
authors.lastname: Watson
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Cheng
authors.forename: Gary M
authors.initials: GM
authors.lastname: Freedman
authors.forename: Andre
authors.initials: A
authors.lastname: Konski
authors.forename: John P
authors.initials: JP
authors.lastname: Hoffman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000276:immunology / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000601:surgery*; D010386:Pelvic Neoplasms / Q000276:immunology / Q000601:surgery*; D011446:Prospective Studies; D012086:Reoperation; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen